drugset / Trial / NCT02283957

A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

NCT02283957

Phase 2 Completed 119 enrolled Centrexion Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

Study 4975-MN-202 is a double-blind, placebo-controlled, parallel group, single-injection study in which subjects will be randomized to receive three doses of CNTX-4975 or placebo injected into the intermetatarsal space around a Morton's neuroma. The injection of study medication will be administered by ultrasound-guided needle placement following ankle block anesthesia. The study staff will telephone subjects at Week 1 postinjection and subjects will return to the clinic postinjection at Weeks 2, 4, 8, and 12 for study assessments.

Timeline

Start
2014-10
Primary completion
2015-08
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Capsaicin Small molecule 25 ug Other
Subject Capsaicin Small molecule 200 ug Other
Subject Capsaicin Small molecule 600 ug Other

Indications